Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Spring;14(2):116-119.
doi: 10.1097/ICB.0000000000000668.

THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA

Gregory J Bever  1 , Dan J Kim  1 , Armin R Afshar  1 , James L Rubenstein  2 , Bertil E Damato  1
Affiliations
Case Reports

THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA

Gregory J Bever et al. Retin Cases Brief Rep. 2020 Spring.

Abstract

Purpose: To report the outcome of a previously vitrectomized eye having less lymphoma disease burden compared with the contralateral nonvitrectomized eye over the course of 3.5 years while on systemic chemotherapy.

Methods: Case report.

Results: A 51-year-old man with vitreoretinal lymphoma with central nervous system involvement underwent vitrectomy in his left eye. Over the following 3.5 years on systemic chemotherapy, the left eye had less lymphoma disease burden compared with the contralateral nonvitrectomized right eye.

Conclusion: Therapeutic vitrectomy may be a useful adjunct to systemic chemotherapy in vitreoretinal lymphoma, particularly in cases of vitreous predominant disease manifestation.

PubMed Disclaimer

Conflict of interest statement

The remaining authors have no financial interests to disclose.

None of the authors has any conflicting interests to disclose.

Figures

Fig. 1
Fig. 1
Fundus photographs showing the nonvitrectomized right eye and previously vitrectomized left eye throughout a 3.5-year course of systemic chemotherapy for central nervous system/retinal lymphoma. A. Right and left eyes in November 2013, a few months after starting systemic chemotherapy. Neither eye shows vitreous or retinal involvement. B. In March 2015, the right eye developed vitreal involvement, despite continued systemic chemotherapy, whereas the left eye remained free of disease. C. Despite additional salvage rituximab therapy, in September 2015, the right eye continued to show vitreal involvement, whereas the left eye was quiet. D. In January 2017, the vitreal involvement continued to worsen in the right eye, whereas the left eye was still without vitreal or retinal involvement on systemic chemotherapy.
See this image and copyright information in PMC

References

    1. Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59:503–516. - PubMed
    1. Pe’er J, Hochberg F, Foster C. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2009;17:299–306. - PubMed
    1. Margolis L, Fraser R, Lichter A, Char DH. The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer. 1980;45:688–692. - PubMed
    1. Batchelor T, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003;9:711–715. - PubMed
    1. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383–388. - PubMed

Publication types

Substances